Abstract:530 Background: Detecting post-surgical residual disease is a critical clinical requirement in resectable hepatocellular carcinoma (HCC). Previous studies focused on specific genomic regions have indicated that ctDNA holds promise as a tool for prognostic assessment. Nevertheless, these methods exhibited limited sensitivity and failed to meet the minimal residual disease (MRD) threshold. Here we report the prognostic value of MRD profiling in HCC patients who have undergone hepatectomy. Methods: This retrospective study involved 88 HCC patients who underwent surgical resections in China, from January to May in 2016. During surgery, tumor and normal tissue specimens were collected. Plasma samples were obtained 7 days post-surgery. PredicineBEACON, a baseline tissue- or blood-informed MRD assay, was used for MRD profiling. This entailed identifying tumor-specific mutations through whole exon sequencing of tissue samples. Subsequently, a personalized MRD panel, selecting up to 50 mutations via bioinformatics pipelines merged with a fixed panel featuring 500 tumor actionable hotspots, was created for each patient. To detect MRD in post-surgery plasma samples, we employed ultra-deep sequencing at a coverage of 100,000X, utilizing the designed panel. Results: In the cohort of 88 patients, the distribution based on Barcelona Clinic Liver Cancer (BCLC) staging was as follows: 79.5% stage A (N=70), 12.5% stage B (N=11), and 8.0% stage C (N=7,). The MRD assay identified 36 patients as MRD+ and 52 patients as MRD-. We observed significant correlations between MRD status and both relapse-free survival (RFS) and overall survival (OS). For MRD+ patients, the median RFS was 17.1 months, while it was not reached for MRD- patients (p=0.0013). Likewise, the median OS for MRD+ patients was 40.1 months, in contrast to it not being reached for MRD- patients (p=0.0012). The MRD positivity rate stood at 100% in stage C patients, a significantly higher percentage compared to the rates observed in stage B (36.4%, p=0.0256) and stage A (36.2%, p=0.0042). Significantly, MRD status emerged as a pivotal prognostic differentiator among clinically low-risk patients in stage A: among MRD+ patients, the median RFS was 23.3 months, whereas it was not reached for MRD- patients (p=0.05). Additionally, the median OS of both MRD+ and MRD- was not reached but their survival curves showed significant differences (p=0.038). Conclusions: This study demonstrated the clinical utility of ctDNA MRD assay in patients with resectable HCC, as notably evident in the robust detection of MRD using plasma samples collected 7 days after surgery. Furthermore, the assessment of post-surgical MRD status provided valuable prognostic insights into both patient survival and the risk of disease relapse. ctDNA MRD status played a pivotal role as a prognostic differentiator, particularly among clinically low-risk patients.

Loss of Heterozygosity at D14S62 and D14S51 Detected by a Simple and Non-Radioactive Method in Plasma DNA is a Potential Marker of Metastasis and Recurrence after Curative Hepatic Resection in Hepatocellular Carcinoma.

[Loss of Heterozygosity of Plasma Circulating DNA from Hepatocellular Carcinoma Patients and Its Clinical Significance].

Clonal Origin of Hepatocellular Carcinoma and Recurrence after Liver Transplantation

[Microsatellite Alterations of Circulating DNA in the Plasma of Patients with Hepatocellular Carcinoma].

The Prognostic Value of Circulating Plasma DNA Level and Its Allelic Imbalance on Chromosome 8p in Patients with Hepatocellular Carcinoma

The Roles of Loss of Heterozygosity at 8p22 in the Molecular Classification of Patients with Hepatocellular Carcinoma, with Special Reference to Survival after Surgical Operation

Relationship Between the Loss of Heterozygosity of Nm23-H1 Gene and the Metastasis in Lung Cancer

The value of chromosomal loss of heterozygosity in prognosis prediction of hepatocellular carcinoma patients with curative resection

Loss of Heterozygosity at D8S298 is a Predictor for Long-term Survival of Patients with Tumor-Node-Metastasis Stage I of Hepatocellular Carcinoma

The Association of Frequent Allelic Loss on 17p13.1 with Early Metastastic Recurrence of Hepatocellular Carcinoma after Liver Transplantation

Loss of Heterozygosity on Chromosome 10Q22-10Q23 and 22q 11.2- 22q 12.1 and P53 Gene in Primary Hepatocellular Carcinoma

Aberrant Methylation Status of SPG20 Promoter in Hepatocellular Carcinoma: A Potential Tumor Metastasis Biomarker.

The prognostic value of chromosomal loss of heterozygosity in molecular staging for TNM stage Ⅰ of hepatocellular carcinoma

Allelic Imbalance Regions on Chromosomes 8p, 17p and 19p Related to Metastasis of Hepatocellular Carcinoma: Comparison Between Matched Primary and Metastatic Lesions in 22 Patients by Genome-Wide Microsatellite Analysis

Genetic Variations in Plasma Circulating DNA of HBV-Related Hepatocellular Carcinoma Patients Predict Recurrence after Liver Transplantation

Plasma Dna Methylation Analysis In Predicting Short-Term Recurrence Of Surgical Patients With Non-Small Cell Lung Cancer (Nsclc)

Plasma Cell-Free Adenomatous Polyposis Coli Gene Promoter Methylation as a Prognostic Biomarker for Hepatocellular Carcinoma

Serial Circulating Tumor DNA to Predict Early Recurrence in Patients with Hepatocellular Carcinoma: a Prospective Study.

Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature

Prognostic value of minimal residual disease profiling in resectable hepatocellular carcinoma.

A Prognostic Fingerprint in Liver Transplantation for Hepatocellular Carcinoma Based on Plasma Metabolomics Profiling.